Odile Beyne‐Rauzy

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

Raphaël Itzykson, Olivier Kosmider, Aline Renneville et al. · Journal of Clinical Oncology · 2013 · 545 citations

Medicine, Genetics, Oncology +17

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag et al. · Blood · 2011 · 480 citations · Full text

Medicine, Hematology, Pharmacology +14

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Raphaël Itzykson, Olivier Kosmider, Thomas Cluzeau et al. · Leukemia · 2011 · 465 citations

Medicine, Molecular Genetics, Oncology +16

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacology +10